February 13, 2026 Fourth Quarter and Full Year 2025 Earnings Call Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995, including, without limitation, the slide entitled "2026 Outlook" and those that are based on current expectations, estimates and projections about the industries in which we operate and management's views, plans, objectives, projections, beliefs ...

Financial Data and Key Metrics Changes - For Q4 2025, sales volumes increased by 8.2% compared to the same period last year, and for the full year 2025, there was a 7.2% increase relative to 2024 [8] - EBITDA for Q4 2025 reached PEN 158.7 million, an 11.4% increase year-over-year, while full year EBITDA was PEN 584.2 million, marking a 6.4% year-over-year increase when excluding one-off expenses [9][10] - Consolidated net income for Q4 2025 was negative due to transactional expenses, but excluding these, net income would have been PEN 59.8 million, a 19.6% increase over the same period last year [26] Business Line Data and Key Metrics Changes - Cement sales in Q4 2025 increased by 13.6%, driven by strong demand in the self-construction sector, while for the full year, cement sales rose by 8.7% compared to 2024 [19][20] - Sales of concrete, pavement, and mortar decreased by 25.1% year-over-year in Q4 2025, primarily due to lower sales volume from the halted Motupe Riverbank Defense Project, but increased by 6.3% for the full year [21][23] - Precast materials sales decreased by 16% in Q4 2025 but increased by 3% for the full year, driven by higher demand from the public sector [25] Market Data and Key Metrics Changes - The growth in sales volumes was attributed to stronger demand for infrastructure projects and consistent performance in the self-construction segment [8] - The agro-industrial and fishing sectors, key income drivers in the north, contributed to the elevated demand for cement [20] Company Strategy and Development Direction - The acquisition agreement with Holcim for a controlling stake in Cementos Pacasmayo is seen as a strong endorsement of the company's long-term strategy and operational excellence [5][6] - The company aims to promote sustainable development and create new opportunities while contributing to the growth of Peru and the wider region [7] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in maintaining EBITDA margins at current levels, with potential improvements due to energy-saving projects planned for the second half of the year [36] - The company anticipates a stronger year in 2026 in terms of volumes and competitive pricing, which should support revenue growth and stable EBITDA margins [38] Other Important Information - The company achieved three-star recognition from Peru's Minister of Environment for reducing greenhouse gas emissions, reflecting its commitment to sustainability [11] - Cementos Pacasmayo has been recognized as the industry leader in the Merco ESG Sustainability Ranking for ten consecutive years, highlighting its focus on sustainability [12][13] Q&A Session Summary Question: Details about the transaction with Holcim and pending steps - The transaction involves Holcim acquiring Inversiones ASPI, which controls 60.01% of Pacasmayo, pending regulatory approval from Indecopi, which is expected to be approved soon [29] Question: Why acquisition-related expenses are high - Most expenses are related to long-standing change of control issues, with part of the costs to be assumed by Hochschild, and the board deemed these expenses reasonable given the share price [30][32] Question: Recognition of PEN 77 million in expenses related to the Holcim transaction - The decision to incur these costs was based on contractual obligations and was approved by the board, with no anticipated impediments from regulatory authorities [32] Question: Expectations for project-related disruptions and margin pressures - Management believes EBITDA margins should remain stable or improve slightly, with expectations for increased spending from authorities later in the year [36] Question: Guidance on revenue growth and EBITDA margins for 2026 - Management is optimistic about volume growth and stable EBITDA margins, with expectations for efficiencies to enhance margins in the second half of the year [38]

Financial Data and Key Metrics Changes - The company closed the quarter with a 16.9% ROE and 19% for the full year, reflecting record high net income and diversification of revenue sources across various segments [16][45] - Net interest income increased by 4.2%, driven by loan portfolio growth and a contraction in interest expenses, resulting in a NIM of 6.6% [20][43] - The NPL ratio stood at 4.5%, indicating improved asset quality, while the cost of risk was 1.8% [19][42] Business Line Data and Key Metrics Changes - In Universal Banking, BCP reinforced its leadership in Peru, serving over 3.2 million loan clients and achieving a full-year ROE of 24.7% [9][25] - Microfinance, through Mibanco, delivered double-digit loan growth and improved profitability, with a NIM of 15.2% [10][34] - The insurance and pensions business, Grupo Pacífico, achieved a solid ROE of 21.4%, with net income rising 13% [36][37] Market Data and Key Metrics Changes - Peru's GDP grew around 3.5% in 2025, supported by strong domestic demand and high commodity prices [6][22] - In Colombia, GDP growth was around 2.7%, while inflation accelerated to 4.51% [8][24] - Chile's GDP also expanded around 2.7%, driven by investment, with inflation slightly above target [8] Company Strategy and Development Direction - The company aims to expand financial inclusion, deepen risk and capital discipline, scale AI and digital platforms, and build trust through operational excellence [13] - A strategic acquisition of Helm Bank for $180 million aims to enhance cross-border capabilities and strengthen the U.S. offering [14][15] - The company plans to continue investing in data transformation and disruptive initiatives to bolster long-term competitive positioning [47] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about Peru's economic stability and growth potential, expecting GDP growth around 3.5% in 2026 [22][46] - The company anticipates total loan growth of approximately 8.5% in 2026, driven primarily by retail banking [46] - Despite local political uncertainties, management believes the fundamentals are in place to support profitability levels [49] Other Important Information - Yape, the company's digital wallet, closed the year with nearly 16 million monthly active users, significantly contributing to revenue growth [12][31] - The company expects non-interest income growth to pick up in the low double digits in 2026, driven by increased activity and diversification efforts [47] Q&A Session Summary Question: Update on political outlook and upcoming elections - Management noted that López Aliaga is leading the polls with 12%, while Keiko Fujimori follows at 8%, with a significant portion of undecided voters [51][53] - The elections for Congress members will occur on April 12, 2026, which is expected to provide more political stability [56][57] Question: Expectations for operating expenses growth - Management indicated that operating expenses are expected to moderate compared to 2025, with a focus on achieving operational leverage from ongoing investments [60][62] Question: Yape's revenue contribution and cost of risk - Yape's lending now represents over 20% of revenue, with a shift towards multi-installment loans expected to maintain controlled provisioning levels [69][71]

Financial Data and Key Metrics Changes - For the full year of 2025, the company reported a 3% local currency revenue growth, a 10% local currency adjusted EBITDA growth, and a 15% local currency adjusted EPS growth [5][22] - The overall adjusted EBITDA margin improved by 100 basis points [5] - In the fourth quarter, local currency revenue grew by 2%, while adjusted local currency operating profit remained flat [5][22] Business Line Data and Key Metrics Changes - The Color Group achieved 7.4% local currency revenue growth and 16.9% local currency operating profit growth for the year, with an adjusted EBITDA margin improvement to 23.7% from 22.1% [8][10] - The Flavors and Extracts Group experienced a 1.3% decline in local currency revenue but a 3.4% increase in local currency operating profit, with an adjusted EBITDA margin of 16.7% [10][12] - The Asia Pacific Group delivered 2.4% local currency revenue growth and 3.8% local currency operating profit growth for the year [12][13] Market Data and Key Metrics Changes - The Color Group's performance is driven by strong momentum in natural color conversions, particularly in the U.S., Canada, and parts of Latin America [6][7] - The Flavors and Extracts Group faced challenges due to severe weather events impacting agricultural ingredients, leading to a one-time inventory loss of approximately $3 million [11][12] - The Asia Pacific Group is expected to recover from regional demand disruptions, with a bounce back anticipated in the latter half of 2026 [12][14] Company Strategy and Development Direction - The company is focused on investing in research and development, production capacity, and a resilient supply chain to support customer needs during the natural color conversion process [7][8] - The goal is to capture a substantial portion of the $1 billion sales opportunity from natural color conversions, with significant capital expenditures planned [16][17] - The company anticipates a ramp-up in natural color inventory throughout 2026 and into 2027 [17] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving double-digit growth in the Color Group for 2026, driven by natural color conversions [15][38] - The company expects mid-single to high single-digit revenue growth for the Flavors and Extracts and Asia Pacific Groups in 2026, with a stronger performance anticipated in the second half of the year [15][92] - Management acknowledged that the first half of 2026 may see challenges in profit leverage due to ongoing investments [15][27] Other Important Information - The company plans to invest $150 million to $170 million in capital expenditures for 2026, with a focus on natural color conversion-related investments [16][25] - The adjusted tax rate for the fourth quarter of 2025 was 17.1%, down from 24.9% in the prior year [23] Q&A Session Summary Question: Conversion opportunity and pipeline for 2026 - Management indicated that approximately $5 million in conversion revenue was invoiced in Q3 and Q4 of 2025, with expectations for acceleration in Q3 and Q4 of 2026 as customer deadlines approach [34][37] Question: Impact of FDA changes on conversion timing - Management believes that FDA guidance will not materially change the timing of brand conversions, as customer commitment to conversion is driven by consumer demand [40][75] Question: Operating leverage and investment details - Management acknowledged that investments in technical personnel and R&D are impacting operating leverage, but these investments are necessary for achieving long-term sales goals [42][44] Question: Confidence in flavors and extracts improvement - Management expressed confidence in mid-single-digit revenue growth for the Flavors and Extracts Group, driven by recovery in agricultural ingredients and improved operational efficiency [89][92] Question: Update on Asia Pacific Group's performance - Management expects a return to revenue and profit growth in the Asia Pacific Group as logistical issues stabilize, with mid-single-digit growth anticipated for the year [92][93]

Financial Data and Key Metrics Changes - For Q4 2025, sales volumes increased by 8.2% year-over-year, while full-year sales grew by 7.2% compared to 2024, driven by demand for infrastructure projects and self-construction [5][10] - EBITDA for Q4 2025 reached PEN 158.7 million, an 11.4% increase year-over-year, while full-year EBITDA was PEN 584.2 million, marking a 6.4% increase when excluding one-off expenses [5][6][10] - Consolidated net income for Q4 2025 was negative due to transactional expenses, but would have been PEN 59.8 million, a 19.6% increase year-over-year if excluding these expenses [15][16] Business Line Data and Key Metrics Changes - Cement sales in Q4 2025 increased by 13.6%, primarily due to strong demand in the self-construction sector, while full-year cement sales rose by 8.7% compared to 2024 [12][14] - Sales of concrete, pavement, and mortar decreased by 25.1% year-over-year in Q4 2025, attributed to the Motupe Riverbank Defense Project being on standby, but full-year sales increased by 6.3% [13][14] - Precast materials sales decreased by 16% in Q4 2025, but full-year sales increased by 3%, driven by public sector demand [15] Market Data and Key Metrics Changes - The company achieved three-star recognition from Peru's Minister of Environment for reducing greenhouse gas emissions, reflecting its commitment to sustainability [7][8] - The company maintained a top-tier position in the Merco ESG Sustainability Ranking, being recognized as the industry leader for ten consecutive years [8] Company Strategy and Development Direction - The acquisition agreement with Holcim for a controlling stake in Cementos Pacasmayo is seen as a strong endorsement of the company's long-term strategy and operational excellence [3][4] - The company aims to promote sustainable development and create new opportunities in collaboration with Holcim [4] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in maintaining EBITDA margins and expects improvements due to energy-saving projects in the second half of the year [25][26] - The company anticipates a positive outlook for revenue growth and EBITDA margins in 2026, driven by strong volume growth and competitive pricing [26] Other Important Information - Administrative expenses increased by 5.7% in Q1 2025 and by 50% for the full year, mainly due to higher personnel costs from collective bargaining [11] - Selling expenses decreased by 8.3% in Q4 2025 but increased by 40% for the full year due to higher advertising and promotional expenses [12] Q&A Session Summary Question: Details about the transaction with Holcim and regulatory approvals - Management confirmed that the transaction is pending INDECOPI approval and is expected to be approved smoothly [18] Question: Why acquisition-related expenses are high - Most expenses are related to long-standing change of control issues, with part assumed by Holcim, and were approved by the board [19] Question: Recognition of PEN 77 million in expenses related to the Holcim transaction - Management explained that these costs are due to contractual obligations from previous agreements and are considered reasonable given the share price [20][21] Question: Expectations for project-related disruptions and margin pressures - Management believes EBITDA margins will remain stable or improve, with expectations of increased spending from authorities later in the year [25] Question: Guidance on revenue growth and EBITDA margins for 2026 - Management is optimistic about volume growth and stable EBITDA margins, with potential increases due to operational efficiencies [26]

Sensient (NYSE:SXT) Q4 2025 Earnings call February 13, 2026 09:30 AM ET Company ParticipantsLarry Solow - Managing DirectorPaul Manning - Chairman, President, and CEOTobin Tornehl - VP and CFOConference Call ParticipantsGhansham Panjabi - Managing Director and Senior Research AnalystNicola Tang - Managing Director and Senior Equity AnalystOperatorGood morning, and welcome to the Sensient Technologies Corporation 2025 fourth quarter and year-end earnings conference call. All participants will be in listen-on ...

Teva Pharmaceutical Industries Conference Summary Company Overview - **Company**: Teva Pharmaceutical Industries (NYSE: TEVA) - **Date of Conference**: February 13, 2026 - **Key Speaker**: Dr. Eric Hughes, Chief Medical Officer Core Industry Focus - **Industry**: Pharmaceutical, specifically in immunology and drug development Key Points and Arguments Immunology R&D Efforts - Teva is focusing on validated molecular targets in its immunology R&D, including TSLP/IL-13-directed treatments [1][2][3] - The company has a strong antibody and protein engineering group, enhancing its capabilities in developing biosimilars and innovative drugs [4][5] Targeted Approaches - The company is exploring various combinations of molecular targets to increase the probability of success in drug development [5][6] - Teva is agnostic regarding the source of innovation, whether internal or through business development and collaborations [8][10] IL-15-Directed Antibody (408) - Teva is accelerating its IL-15-directed antibody program, targeting vitiligo and celiac disease with timelines set for 2031 and 2034, respectively [12][13] - The company has secured up to $500 million in R&D funding from Royalty Pharma for the vitiligo program, emphasizing the high costs associated with drug development [19][21] Clinical Development Insights - The phase IIb study for vitiligo will require a safety database of approximately 1,400 patients for FDA approval [22] - The company aims to differentiate its IL-15 treatment from existing therapies by potentially offering a quarterly dosing regimen, contrasting with daily treatments of current options [37][39] Mechanistic Rationale - The mechanism of action for IL-15 in vitiligo involves blocking signals that maintain CD8 positive T-cells, which destroy melanocytes [31][33] - In celiac disease, IL-15 is linked to the proliferation of anti-gut lining cells, and blocking it may prevent damage to the gut lining [45][47] Competitive Landscape - Teva's IL-15 antibody is considered more potent than competitors, with a lower rate of anti-drug antibodies [50] - The company is exploring additional indications for its IL-15 treatment, including atopic dermatitis and alopecia areata [51] Future Developments - Teva plans to submit an IND for the TSLP/IL-13 combination by the end of the year, indicating a proactive approach to advancing its pipeline [85] Additional Important Insights - The company acknowledges the high costs of drug development, with $500 million being a reasonable estimate for a vitiligo program [21] - Safety profiles of new treatments are a significant concern, with IL-15 showing promising tolerability compared to existing JAK inhibitors [44] This summary encapsulates the key discussions and insights from the Teva Pharmaceutical Industries conference, highlighting the company's strategic focus on immunology and its innovative approaches to drug development.

Credicorp (NYSE:BAP) Q4 2025 Earnings call February 13, 2026 09:30 AM ET Company ParticipantsAlejandro Pérez-Reyes - CFOAndres Soto - Executive Director of LatAm Equity ResearchBrian Flores - VP of Equity ResearchCarlos Gomez - Head of LatAm Financial InstitutionsCésar Ríos - Chief Risk OfficerEduardo Montero - Head of Insurance and PensionsErnesto Gabilondo - Director of LatAm FinancialsGianfranco Ferrari - CEOMilagros Cigüeñas - Investor Relations OfficerTito Labarta - VPConference Call ParticipantsDaniel ...

Financial Data and Key Metrics Changes - For Q4 2025, revenues increased by 6.2% year-over-year, reaching PEN 559.5 million, driven by higher sales of pack cement and increased sales for infrastructure projects [10] - EBITDA for Q4 2025 reached PEN 158.7 million, an 11.4% increase compared to the same period last year, excluding one-off expenses related to the share purchase agreement with Holcim [6][10] - Full year 2025 EBITDA was PEN 584.2 million, marking a 6.4% year-over-year increase when excluding one-off expenses [7][17] - Net income for Q4 2025, excluding one-off expenses, would have been PEN 59.8 million, a 19.6% increase over the same period last year [16][17] Business Line Data and Key Metrics Changes - Cement sales in Q4 2025 increased by 13.6%, primarily due to robust demand in the self-construction sector, while full year cement sales increased by 8.7% compared to 2024 [12][14] - Sales of concrete, pavement, and mortar decreased by 25.1% year-over-year in Q4 2025, mainly due to lower sales volume from the halted Motupe Riverbank Defense Project [13][14] - Precast materials sales decreased by 16% in Q4 2025 but increased by 3% for the full year, driven by higher demand from the public sector [16] Market Data and Key Metrics Changes - The company experienced strong momentum in sales volumes, with an 8.2% increase in Q4 2025 compared to the same period last year, and a 7.2% increase for the full year 2025 relative to 2024 [6] - The growth was attributed to stronger demand for infrastructure projects and consistent performance in the self-construction segment [6] Company Strategy and Development Direction - The acquisition agreement with Holcim for a controlling stake in Cementos Pacasmayo is seen as a strong endorsement of the company's long-term strategy and operational excellence [4][5] - The company aims to promote sustainable development and contribute to the growth of Peru and the wider region [5] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the momentum built and the positive outlook for future performance, emphasizing operational excellence and profitability [9] - The company anticipates that EBITDA margins will remain stable or increase slightly due to energy-saving projects planned for the second half of the year [26][27] Other Important Information - The company achieved three-star recognition from Peru's Minister of Environment for reducing greenhouse gas emissions, reinforcing its commitment to sustainability [7][8] - The company maintains a top-tier position in the Merco ESG Sustainability Ranking, recognized as the industry leader for ten consecutive years [8] Q&A Session Summary Question: Details about the transaction with Holcim and regulatory approvals - Management confirmed that the transaction is pending Indecopi approval and is expected to be approved in the coming months, with no anticipated impediments [19] Question: Acquisition-related expenses and their justification - Management explained that most transaction expenses are related to long-standing change of control issues, with part of the expenses to be assumed by Holcim [20][21] Question: Future project-related disruptions and margin pressures - Management indicated that while each project has unique circumstances, they expect EBITDA margins to remain stable or improve due to upcoming energy-saving projects [26] Question: Guidance on revenue growth and EBITDA margins for 2026 - Management expressed optimism about volume growth and stable EBITDA margins for 2026, citing competitive pricing and operational efficiencies [27]

Q4 2025 Financial and Operating Results © Copyright 2026 Galiano Gold. All rights reserved. February 13, 2026 Forward Looking Information & Cautionary Statements Certain statements and information contained in this presentation constitute "forward-looking statements" within the meaning of applicable U.S. securities laws and "forward-looking information" within the meaning of applicable Canadian securities laws, which we refer to collectively as "forward-looking statements". Forward-looking statements are st ...